DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for postmenopausal atrophic vaginitis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePostmenopausal atrophic vaginitis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for postmenopausal atrophic vaginitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
casein kinase 1 gamma 3 (CSNK1G3) — CSNK1G3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2IZR · 1.3 Å · ligand {(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE (BRK). Experimental structure, not a prediction.
What the evidence adds up to
Atrophic vaginitis is an oestrogen-dependent condition, and the mainstay of management is oestrogen replacement therapy, which should begin when ovarian decline starts at menopause or when symptoms appear. Lubricants, vaginal moisturisers, and regular sexual activity are described as helpful adjuncts. A 1969 report on desquamative inflammatory vaginitis, a condition that resembles atrophic vaginitis but occurs in women with normal oestrogen levels, states that intravaginal corticosteroid preparations proved the most effective treatment among those tested, though the disease runs a protracted course with or without treatment.
A 2023 randomised clinical trial with 70 postmenopausal women compared Vagiheal Gel against Estromarin cream (0.625 mg/g conjugated oestrogen). The Estromarin group used 2.5 grams intravaginally for 21 nights, took one week off, then repeated for another 21 nights. The Vagiheal group used 2.5 grams for 7 consecutive nights, then twice weekly for two months. The mean scores for dryness, itching, and burning decreased significantly in both groups (p=0.01). For dyspareunia, the reduction was more obvious with Vagiheal gel. The authors conclude that Vagiheal gel appears a suitable alternative for treating atrophic vaginitis.
No trial has yet established a standardised comparator for Vagiheal against placebo, and the 2023 study did not report objective measures such as vaginal pH or maturation index. The 1969 description of desquamative inflammatory vaginitis remains a separate entity with no confirmed cause and no large-scale treatment trial. What is still missing is a placebo-controlled trial large enough to stratify patients by symptom severity and oestrogen status, and funding to test whether any non-hormonal agent works better than existing oestrogen-based therapy in the long term.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Postgraduate Medicine · 1992 · 14 citations
Atrophic vaginitis
AbstractAtrophic vaginitis is not only treatable but preventable. Because the vagina is an estrogen-dependent organ, the mainstay of management is estrogen replacement therapy, which should be initiated with the onset of ovarian decline at menopause or when a woman presents with symptoms of atrophic vaginitis. Lubricants and vaginal moisturizers may be useful adjuncts. Regular sexual activity is also helpful in maintaining a healthy, functional vagina.
AbstractAbstract Eight cases of a newly described type of vaginitis are reported. In many respects, this vaginitis resembles atrophic vaginitis, although it appears in women with normal estrogen levels. Its etiology is as yet undetermined. With or without treatment, the disease runs a protracted course. Thus far, intravaginal applications of preparations containing a corticosteroid have proved to be the most effective treatment.
Current Women s Health Reviews · 2023 · 0 citations
Comparing the Effect of Vagiheal Gel and Estromarin Cream on AtrophicVaginitis in Postmenopausal Women-A Randomized Clinical Trial
AbstractPropose: This study was done to reduce atrophic vaginitis. Aim: This study aimed to compare the effects of Vagiheal Gel and Estromarin in reducing atrophic vaginitis. Methods: This study was a randomized clinical trial with a parallel design. 70 postmenopausal women who had dyspareunia and were referred to the health clinics of Arak, Iran were included in this study. Patients were assigned to one of the 2 groups of Vagiheal or Estromarin. The patients in the Estromarin group were provided with 0.625 mg/g vaginal cream for intravaginal use 2.5 grams for 21 nights. After one week of medicinal rest, they were prescribed 2.5 grams of intravaginal cream for another 21 nights, and then, one week of medicinal rest was considered. The patients in the Vagiheal group were prescribed 2.5 grams of Vagiheal Gel by inserting the applicator into the vagina when sleeping for 7 consecutive nights, then as a maintenance treatment for 2 times a week for 2 months. The severity of the symptoms was measured by a visual Analog scale(VAS) before, 2 weeks, 1 month, and 2 months after starting the program. The data were analyzed using T-test, Mann-Whitney, Chi-square, and Friedman test. Results: The results of atrophic vaginitis follow-up processes showed that the mean of dryness, itching, and burning of the vagina in both groups significantly decreased after the intervention (p=0.01); however, the decrease of these symptoms in the dyspareunia group was more obvious in Vagiheal gel. Conclusion: It seems that Vagiheal gel is a suitable alternative to atrophic vaginitis treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
